Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIOLET neoadjuvant optimization trial in HR-positive/HER2-negative early breast cancer
2026-525457-37-00Phase 2Authorised
- Sponsor
- Mario Negri Institute for Pharmacological Research
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of abemaciclib in breast cancer (2 arms), sponsored by Mario Negri Institute for Pharmacological Research. Primary endpoints: Chemotherapy avoidance with NET plus abemaciclib and Surgical de-escalation rate. Planned start Oct 2026; status: authorised.
02
Drugs
abemaciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2026-525457-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525457-37-00.